Cost drivers of locally advanced rectal cancer treatment—An analysis of a leading healthcare insurer

A bibliometric analysis was performed using a machine learning bibliometric methodology in order to evaluate the research trends in locally advanced rectal cancer treatment between 2000 and 2020. Information regarding publication outputs, countries, institutions, journals, keywords, funding, and citation counts was retrieved from Scopus database. During the search process, a total of 2370 publications were identified. The vast majority of papers originated from the United States of America, reflecting also its research drive in the collaboration network. Neoadjuvant treatment was the topic most studied in the highly cited studies. New keywords, including neoadjuvant chemotherapy, multiparametric magnetic resonance imaging, circulating tumor DNA, and genetic heterogeneity, appeared in the last 2 years. The quantity of publications on locally advanced rectal cancer treatment since 2000 showed an evolving research field. The ‘new’ keywords explain where research is presently heading.

Download Full-text

Effect of Carbogen to Chemoradiation in Volume of Rectal Cancer

ACTA MEDICA IRANICA ◽

10.18502/acta.v58i1.3702 ◽

2020 ◽

Author(s):

Christina Hari Nawangsih ◽

Soehartati Gondhowiardjo ◽

Sofia Mubarika Haryana ◽

Soeharyo Hadisaputro ◽

Catharina Suhart ◽

...

Keyword(s):

Rectal Cancer ◽

Treatment Group ◽

Tumor Volume ◽

Standard Treatment ◽

Locally Advanced ◽

Advanced Rectal Cancer ◽

Locally Advanced Rectal Cancer ◽

Control Group ◽

Post Test ◽

Rectal Cancer Treatment

The outcome of inoperable rectal cancer treatment by chemotherapy, radiotherapy, and targeted therapy are still unfavorable. Carbogen is a combination of 98% oxygen and 2% carbon dioxide proven effective as chemoradiosensitizer. The aim of this study is to know the effect of concurrent carbogen and chemoradiotherapy in locally advanced rectal cancer by measuring the shrinkage of the tumor volume. The design of this study was randomized true experimental 2 groups pre and post-test-controlled design. Samples were patients with locally advanced rectal cancer. MRI of the pelvis before and 4-8 weeks after the chemoradiation were examined. A total of 28 subjects were randomized to 14 patients who received concurrent chemoradiation with carbogen (treatment group) and 14 patients chemoradiation (control) The tumor shrinkage in the treatment group (13.08 to 6.08 cm3 ) was significantly higher compared to the control group (18.00 to 12.83 cm3 ). Supplementation of carbogen to standard treatment chemoradiation for locally advanced rectal cancer significantly shrinkage the tumor volume.

Download Full-text

Neoadjuvant chemoradiotherapy in rectal cancer

memo - Magazine of European Medical Oncology ◽

10.1007/s12254-020-00594-0 ◽

2020 ◽

Vol 13 (3) ◽

pp. 329-333 ◽

Cited By ~ 1

Author(s):

Christoph Reinhold Arnold ◽

Julian Mangesius ◽

Robert Jäger ◽

Ute Ganswindt

Keyword(s):

Rectal Cancer ◽

Checkpoint Inhibitors ◽

Locally Advanced ◽

Neoadjuvant Chemoradiotherapy ◽

Advanced Rectal Cancer ◽

Short Review ◽

Locally Advanced Rectal Cancer ◽

Short Course ◽

Rectal Cancer Treatment ◽

Total Neoadjuvant Therapy

Summary Neoadjuvant chemoradiotherapy is a well-established standard treatment for locally advanced rectal cancer and has led to a remarkable improvement in local control. However, distant recurrences still pose a notable threat and local failure, albeit increasingly rare, can lead to unfavorable clinical situations. In this short review, we discuss three promising new strategies to improve rectal cancer treatment: total neoadjuvant therapy, short course radiotherapy, and immune checkpoint inhibitors.

Download Full-text